News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ensemble Therapeutics Corporation Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies


11/12/2012 9:45:46 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today positive preclinical oral efficacy data with its first-in-class small molecule Interleukin-17 (IL-17) antagonists. A presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting, taking place November 9-14, 2012 in Washington, DC, revealed that the company’s Ensemblins have strong oral activity as antagonists of IL-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s disease and inflammatory bowel disease.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES